Cyclic guanosine monophosphate/adenosine monophosphate synthase (cGAS), innate immune responses, and viral hepatitis
Eloi R. Verrier, Michaela U. Gack, Thomas F. Baumert – 22 April 2014
The multifaceted functions of ribavirin: Antiviral, immunomodulator, or both?
Mario U. Mondelli – 22 April 2014
Liver transplantation outcomes for Australian Aboriginal and Torres Strait Islanders
- Read more about Liver transplantation outcomes for Australian Aboriginal and Torres Strait Islanders
Mohamed A. Chinnaratha, Uthayanan Chelvaratnam, Katherine A. Stuart, Simone I. Strasser, Geoffrey W. McCaughan, Paul Gow, Leon A. Adams, Alan J. Wigg, on behalf of the Australia and New Zealand Liver Transplant Clinical Study Group – 21 April 2014 – An increased liver disease burden has been reported for Aboriginal and Torres Strait Islanders (ATSIs) in Australia; however, few proceed to liver transplantation (LT).
Reply
Neung Hwa Park, Seok Won Jung, Eun‐Soon Shin, Young‐Hwa Chung – 20 April 2014
Prognostic impact of telomere maintenance gene polymorphisms in hepatocellular carcinoma patients: Some issues need to be clarified
Fei Liu, Wen‐Tao Wang, Yong‐Gang Wei, Bo Li – 20 April 2014
Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease
Pierre Bedossa, the FLIP Pathology Consortium – 19 April 2014 – Biopsy is still the gold standard for the diagnosis of nonalcoholic steatohepatitis but the definition may vary among pathologists, a drawback especially in evaluation of biopsies for clinical trials. We previously developed a scoring system (steatosis, activity, fibrosis [SAF]) allowing the use of an algorithm (fatty liver inhibition of progression [FLIP]) for the classification of liver injury in morbid obesity.
Vitamin D deficiency and liver cancer: More than just an epidemiological association?
Massimo Colombo, Angelo Sangiovanni – 19 April 2014
Ursodeoxycholic acid in primary sclerosing cholangitis: If withdrawal is bad, then administration is good (right?)
James H. Tabibian, Keith D. Lindor – 19 April 2014
Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long‐term tenofovir: Virological and clinical implications
Anders Boyd, Joël Gozlan, Sarah Maylin, Constance Delaugerre, Gilles Peytavin, Pierre‐Marie Girard, Fabien Zoulim, Karine Lacombe – 19 April 2014 – Tenofovir (TDF) is considered the ideal treatment for patients coinfected with human immunodeficiency virus (HIV) and hepatitis B virus (HBV). However, certain coinfected patients exhibit incomplete viral suppression, with persistent, and sometimes transient, bouts of HBV replication. The reasons for this, including clinical effect, are unclear.
Iron‐induced oxidative rat liver injury after non–heart‐beating warm ischemia is mediated by tumor necrosis factor α and prevented by deferoxamine
Xianwa Niu, Wen Hua Huang, Bastiaan De Boer, Luc Delriviere, Ling Jun Mou, Gary P. Jeffrey – 19 April 2014 – This study investigated iron‐induced injury after warm ischemia in a non–heart‐beating (NHB) rat liver model and the effects of deferoxamine (DFO). Livers from heart‐beating (HB) rats or rats that were NHB for 60 minutes were stored in University of Wisconsin solution for 5 hours at 4°C [cold storage (CS)] and then were subjected to 2 hours of machine reperfusion (MRP) at 37°C.